PREVAIL: A MULTINATIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ORAL MDV3100 IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE METASTATIC PROSTATE CANCER WHO HAVE FAILED ANDROGEN DEPRIVATION THERAPY
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006834/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the benefit of enzalutamide versus placebo as
assessed by overall survival and progression-free survival in patients with progressive
metastatic prostate cancer who have failed androgen deprivation therapy but not yet received
chemotherapy.
提供机构：
Vivli
创建时间：
2021-04-02
